Reducing LPS Risk: Best Practices in Peptide Production
Proactive endotoxin risk management is more effective and economical than reactive testing and rejection. This article outlines the best practices that leading peptide manufacturers employ to minimize LPS risk throughout their operations.
Facility Design
- Appropriate cleanroom classifications for each manufacturing stage
- Proper air handling with HEPA filtration
- Unidirectional workflow to prevent cross-contamination
- Easy-to-clean surfaces that resist biofilm formation
Water System Management
- Use of Water for Injection (WFI) quality water for critical steps
- Regular sanitization of water purification and distribution systems
- Continuous monitoring of water quality at point of use
- Elimination of dead legs and low-flow zones where bacteria can proliferate
Equipment and Consumables
- Depyrogenation of all glass and metal equipment (250°C for 30+ minutes)
- Use of single-use, certified endotoxin-free consumables where practical
- Validated cleaning procedures for reusable equipment
- Regular equipment maintenance to prevent biofilm formation
Personnel Practices
- Comprehensive gowning procedures for cleanroom entry
- Regular training on aseptic technique
- Limitation of personnel in critical manufacturing areas
- Monitoring of personnel compliance with cleanroom protocols
Process Controls
- In-process endotoxin testing at critical control points
- Validated endotoxin removal steps for products requiring ultra-low levels
- Environmental monitoring with trending and root cause analysis
- Corrective and preventive action (CAPA) systems for contamination events
The Evolve Aminos Commitment
Our manufacturing standards reflect these best practices, ensuring that every peptide we provide has been produced under conditions designed to minimize endotoxin risk.